Rheumatology

You appear very angry. Derm access isn't much better than Rheum access. The issue is COVERAGE and pull through. Novartis has a long way to go with that. The TNF's get RX's FIRST and are usually HIGHLY effective. That's not the case in derm. Cosentyx is extremely effective in derm an often MORE effective than a TNF. In rheum...NOT SO MUCH. Get your facts straight. There's not a lot of Ank Spon out there. There isn't really a lot of PSA. It's PSO and RA. So, before you become angry with your response, READ and COMPREHEND. Managed care dictates everything. And yes, if you don't have rheum access you are screwed.

 

He needs anger management or life coach.

 

I agree.

 

You confuse anger with frustration over ignorant posts. Let me filet your suppositions:
1) "Derm access isn't much better than Rheum access."
This is your where you expose your ignorance - I simply have no response for this naive statement.
2) "The issue is COVERAGE and pull through. Novartis has a long way to go with that."
No shit. And this differed from the Derm launch how?? Don't comment unless you know how the Novartis patient access programs work.
3) "The TNF's get RX's FIRST and are usually HIGHLY effective. That's not the case in derm. Cosentyx...In rheum...Get your facts straight.
Anytime you'd like to compare biologic knowledge vaults in rheum and derm... While TNF's do get used first, your next couple of comments are at best 50/50.
4) "...not a lot of AS or PsA."
Who cares? Also, if you knew anything about AS, you'd know that estimates of those undiagnosed could double the number of known cases.

Class dismissed.

 

What is E Hanover's position? Did not get insight from meeting. The Future Trial data are not spectacular?

 

Let me see if I can properly "filet your suppositions".

First of all, you brought up access. Yes, rheum access is even worse than derm access.
Secondly, there is a huge difference with Cosentyx between derms and rheums. Derms..have , overall, not been happy with the results their patients have seen in some cases. Cosentyx works in derm. It works well. Derms will fight for Cosentyx due to the efficacy some patients see over TNF's. In rheums..not so much. Rheums are , overall, very happy with the efficacy that the patients see with RA and PSA with TNF's. The TNF's clearly work well on protecting joints. I know..I've sold for a long time in both rheum and derm. The Cosentyx data just isn't offering much over what Enbrel or Humira due. Plus, the access is terrible for Cosentyx. So, there. Case dismissed.

 

Who cares about how much AS there is...drug companies. not much AS, not many scripts. Cosentyx needs an RA indication to fight.

 

This is just too damn easy. "Derms...have, overall, not been happy with the results their patients have seen in some cases." WTF does that mean exactly? Have another glass & cheers!

 

EXACTLY!

 

Exactly--whatever the poster stated, I think in some cases, derms are not happy with TNF's. What part don't you get? Again...you are angry! You have another glass!!!

 

That's less than 10% of the Rxs that Consentyx competes for with the anti - IL-23/12 and another oral anti- TNF.

 

Cosentyx should do alright in derm but there is not enough money to be had in the Rheum space. The indications are very limited(if we actually get them for PsA and AS) and the territories are too small for enough volume. Glad I am on the Derm side. Feel sorry for those coming here for the Rheum positions.

 

I agree. And, it shows marginal efficacy. Needs RA

 

MB already announced that there is no plan to go after the RA indication. So, rheum focus will be in niche market and difficult to grow. The rheum team will good for 6-8 months, then Sr. executes decides to cut team.

 

Rheum team will essentially be fighting for a small percentage of a crumb. Not likely to be profitable but company is going forward with hiring a salesforce for appearances. Investors like to hear about potential. But if there is so much potential, why weren't Managers hired for Rheumatology salesforce? Derm managers are assuming that responsibility. If you are considering a Rheum position you may want to reconsider. I can't stand how companies screw with reps careers by promising how wonderful it will be when they know the likelihood of success is slim. I love the company but don't want to see anyone get blindsided.

 

when is the ad board meeting for these indications? Will determine how much Rheums want product.

 

That's not true , though, about Rheum managers not being hired. They are currently being hired now. I still do think it's super risky--too small of a market for a high-paid Rheum Sales force. I'm staying put.

 

Very risky

Not good if they decide to cut.

 

Crap drug. crap division.

 

Has anyone heard about a f2f with manager before panel interviews? I had phone interview last week and was told I would hear something by end of week.